NCCN has received a research grant from AVEO and Astellas to evaluate the role of tivozanib in the treatment of solid tumors.
Tivozanib is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors.
NCCN vice president Diane Paul said grant support will fund clinical research in different types of solid tumors designed and carried out by investigators at NCCN Member Institutions.
AVEO chief medical officer William Slichenmyer said they collaborate with NCCN to further advance their understanding of tivozanib through clinical research.